Biohaven Pharmaceutical Holding Co. Ltd.
(NYSE : BHVN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.21%177.760.7%$1347.68m
MRKMerck & Co., Inc. 0.69%93.280.7%$1220.32m
PFEPfizer Inc. 0.90%52.110.9%$1105.14m
LLYEli Lilly & Co. 0.46%328.681.1%$1030.86m
BMYBristol-Myers Squibb Co. 0.19%76.111.0%$993.47m
ABBVAbbVie, Inc. -1.32%151.901.9%$947.56m
AZNAstraZeneca Plc 0.59%65.901.0%$473.76m
SGENSeagen Inc. -0.67%175.605.7%$323.90m
GSKGSK Plc -0.66%43.020.2%$270.63m
TPTXTurning Point Therapeutics, Inc. -0.17%75.030.0%$198.96m
HZNPHorizon Therapeutics Plc -0.88%82.035.4%$172.55m
NVSNovartis AG -1.05%83.400.2%$170.47m
ALNYAlnylam Pharmaceuticals, Inc. -0.13%150.538.1%$150.11m
MRTXMirati Therapeutics, Inc. -1.76%70.691.6%$148.15m
NVONovo Nordisk A/S -0.73%110.430.1%$147.29m

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.